Pooled analyses of eribulin in metastatic breast cancer patients with at least one prior chemotherapy

Eribulin is indicated in the EU for advanced/metastatic breast cancer patients following ≥1 prior chemotherapy for advanced disease, and anthracycline and taxane in adjuvant/metastatic setting. We pooled 1644 patients from two phase III trials and found that eribulin significantly increased survival versus control, particularly in some subgroups of interest like HER2- and triple-negative disease.

• Publication year

  2016

• Venue

  Annals of Oncology

• Publication date

  2016-05-13

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/annonc/mdw203PMID 27177860PMCID 4959925
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Phase III Open-Label Randomized Study of Eribulin Mesylate Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane

  2015influential reference
• Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies

  2014cited by this paper
• Chemotherapy and targeted therapy for women with human epidermal growth factor receptor 2-negative (or unknown) advanced breast cancer: American Society of Clinical Oncology Clinical Practice Guideline.

  2014cited by this paper
• US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status.

  2014influential reference
• ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)

  2014cited by this paper
• US Food and Drug Administration approval overview in metastatic breast cancer.

  2012cited by this paper
• Overall survival as the outcome for randomized clinical trials with effective subsequent therapies.

  2011cited by this paper
• Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study.

  2011influential reference
• The Ongoing Evolution of Endpoints in Oncology

  2010cited by this paper
• Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer.

  2008cited by this paper
• Breast cancer with synchronous metastases: trends in survival during a 14-year period.

  2004influential reference

• Phase II trial of anlotinib-chemotherapy combination in pretreated HER2-negative metastatic breast cancer: therapeutic efficacy and proteomic biomarker profiling.

  2026cites this paper
• Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone-receptor-positive HER2-negative breast cancer: final overall survival analysis of the phase 3 TROPION-Breast01 study.

  2025cites this paper
• Randomized phase II comparison of single-agent carboplatin versus combination of carboplatin and everolimus for advanced triple negative breast cancer

  2025cites this paper
• Ipatasertib combined with non-taxane chemotherapy for patients with previously treated advanced triple-negative breast cancer: the PATHFINDER phase IIa trial

  2025cites this paper
• A meta-analysis and systematic review of the first Trop-2-targeting antibody–drug conjugate (sacituzumab govitecan) in treating metastatic breast cancer

  2025cites this paper
• Efficacy and safety of Eribulin-based chemotherapy in HER2 negative advanced breast cancer patients: a real-world study

  2025cites this paper
• Eribulin Effectiveness and Safety in Metastatic Triple-Negative Breast Cancer: A Narrative Review

  2025cites this paper
• Metastatic triple-negative breast cancer – current treatment strategies in the Nordics: a modified Delphi study

  2025cites this paper
• Intravenous liposomal irinotecan in metastatic triple-negative breast cancer after ≥ 2 prior lines of chemotherapy: a phase Ib study

  2025influential citation
• Second-Line Treatment Options for Patients with Metastatic Triple-Negative Breast Cancer: A Review of the Clinical Evidence

  2025cites this paper
• mTOR inhibitor introduce disitamab vedotin (RC48-ADC) rechallenge microtubule-chemotherapy resistance in HER2-low MBC patients with PI3K mutation

  2024cites this paper
• Eribulin plus carboplatin combination for HER2-negative metastatic breast cancer: a multicenter, real-world cohort study

  2024cites this paper
• Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor–Positive Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer: Primary Results From TROPION-Breast01

  2024cites this paper
• Synergizing Immunotherapy and Antibody–Drug Conjugates: New Horizons in Breast Cancer Therapy

  2024cites this paper
• Subgroup analyses from the phase 3 ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer

  2024cites this paper
• Effects of Eribulin on the RNA Content of Extracellular Vesicles Released by Metastatic Breast Cancer Cells

  2024cites this paper
• Challenges in HER2-low breast cancer identification, detection, and treatment

  2024cites this paper
• Cost-effectiveness of sacituzumab govitecan versus chemotherapy in patients with relapsed or refractory metastatic triple-negative breast cancer

  2023cites this paper
• A phase Ib/II study of eribulin in combination with cyclophosphamide in patients with advanced breast cancer

  2023cites this paper
• TROPION-Breast02: Datopotamab deruxtecan for locally recurrent inoperable or metastatic triple-negative breast cancer.

  2023cites this paper
• Triple negative breast cancer: second and successive lines of treatment

  2023cites this paper
• TROPION-Breast01: Datopotamab deruxtecan vs chemotherapy in pre-treated inoperable or metastatic HR+/HER2- breast cancer.

  2023cites this paper
• Cost-effectiveness of trastuzumab deruxtecan in previously treated human epidermal growth factor receptor 2-low metastatic breast cancer

  2023cites this paper
• Design of Comprehensive System for Screening, Diagnosis, and Treatment of Breast Cancer in Armed Forces

  2022cites this paper
• Current Therapeutic Strategies for Metastatic Triple-Negative Breast Cancer: From Pharmacists’ Perspective

  2022cites this paper
• Sacituzumab Govitecan in Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer

  2022cites this paper
• Comparative review of pharmacological therapies in individuals with HER2-positive advanced breast cancer with focus on hormone receptor subgroups

  2022cites this paper
• Sacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancer—phase 3 ASCENT study subanalysis

  2022cites this paper
• Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer

  2022cites this paper
• Efectividad y seguridad de la eribulina en la vida real en el tratamiento de cáncer de mama metastásico en un hospital general

  2022cites this paper
• Emerging strategies for TNBC with early clinical data: new chemoimmunotherapy strategies

  2022cites this paper
• Major advancements in metastatic breast cancer treatment: when expanding options means prolonging survival

  2022cites this paper
• Prioritising systemic cancer therapies applying ESMO’s tools and other resources to assist in improving cancer care globally: the Kazakh experience

  2022cites this paper
• Eribulin improved the overall survival from the initiation of first-line chemotherapy for HER2-negative advanced breast cancer: a multicenter retrospective study

  2022cites this paper
• Eribulin-trastuzumab combination in HER2-positive metastatic breast cancer: updated results from a Russian observational study

  2021cites this paper
• Eribulin Mesylate for the Treatment of Metastatic Hormone-refractory and Triple-negative Breast Cancer: A Multi-institutional Real-world Report on Efficacy and Safety.

  2021cites this paper
• A transposon screen identifies enhancement of NF-κB pathway as a mechanism of resistance to eribulin

  2021cites this paper
• Clinical Utility of Eribulin Mesylate in the Treatment of Breast Cancer: A Chinese Perspective

  2021cites this paper
• Antibody‐drug conjugate MORAb‐202 exhibits long‐lasting antitumor efficacy in TNBC PDx models

  2021cites this paper
• Eribulin Efficacy on Brain Metastases in Heavily Pretreated Patients with Metastatic Breast Cancer

  2021cites this paper
• Second-line Eribulin in Triple Negative Metastatic Breast Cancer patients. Multicentre Retrospective Study: The TETRIS Trial

  2021cites this paper
• Incorporation of eribulin in the systemic treatment of metastatic breast cancer patients in Australia

  2021cites this paper
• Emerging drugs for the treatment of triple-negative breast cancer: a focus on phase II immunotherapy trials

  2021cites this paper
• Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer

  2021cites this paper
• Эффективность и переносимость эрибулина у пожилых больных

  2021cites this paper
• Eribulin: clinical review and new perspective in advanced breast cancer

  2021cites this paper
• Capecitabine for hormone receptor-positive versus hormone receptor-negative breast cancer.

  2021cites this paper
• Dynamic Changes in Absolute Lymphocyte Counts During Eribulin Therapy Are Associated With Survival Benefit

  2021cites this paper
• A narrative review of chemotherapy in advanced triple negative breast cancer

  2021cites this paper
• Analysis of the efficacy and safety of eribulin therapy in patients with HR+/HER2- metastatic breast cancer pretreated with CDK4/6 inhibitors in real Russian practice

  2021cites this paper
• A phase Ib study of TQB2450 plus anlotinib in patients with advanced triple-negative breast cancer

  2021cites this paper
• Effectiveness and safety of eribulin for human epidermal growth factor receptor 2 negative metastatic breast cancer in a real-world population

  2021influential citation
• The Place of Chemotherapy in The Evolving Treatment Landscape for Patients With HR-positive/HER2-negative MBC.

  2021cites this paper
• Shorter duration of first-line chemotherapy reflects poorer outcomes in patients with HER2-negative advanced breast cancer: a multicenter retrospective study

  2021cites this paper
• Are we ready to embrace novel therapeutic targets for women with AR-positive or AR-negative metastatic Triple-Negative Breast Cancer ?

  2021cites this paper
• BCTT_A_231298 135..150

  2021cites this paper
• Systematic review of Real-World effectiveness of eribulin for locally advanced or metastatic breast cancer

  2020cites this paper
• Progress: Targeted Therapy, Immunotherapy, and New Chemotherapy Strategies in Advanced Triple-Negative Breast Cancer

  2020cites this paper
• Antibody-drug conjugates in metastatic triple negative breast cancer: a spotlight on sacituzumab govitecan, ladiratuzumab vedotin, and trastuzumab deruxtecan

  2020cites this paper
• Prospects of eribulin administration for patients with HR-positive HER2-negative metastatic breast cancer after progression on CDK4/6 Inhibitors: theoretical background and first experience

  2020cites this paper
• Measuring Tumor Epichaperome Expression Using [124I] PU-H71 Positron Emission Tomography as a Biomarker of Response for PU-H71 Plus Nab-Paclitaxel in HER2-Negative Metastatic Breast Cancer.

  2020cites this paper
• Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer (ERIGE trial). Clinical and pharmacogenetic results on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC).

  2020influential citation
• C-Reactive Protein and Absolute Lymphocyte Count Can Predict Overall Survival of Patients Treated With Eribulin

  2020cites this paper
• The efficacy of the combination of eribulin and trastuzumab in advanced HER2-positive breast cancer: the results of Russian observational study

  2020cites this paper
• Utility of the Absolute Lymphocyte Count and Neutrophil/Lymphocyte Ratio for Predicting Survival in Patients with Metastatic Breast Cancer on Eribulin: A Real-World Observational Study

  2020cites this paper
• Use of eribulin as an earlier-line chemotherapy for patients with HER2-negative metastatic breast cancer

  2020cites this paper
• 53BP1 Accumulation in Circulating Tumor Cells Identifies Chemotherapy-Responsive Metastatic Breast Cancer Patients

  2020cites this paper
• Treatment options for Indonesian triple negative breast cancer patients: a literature review of current state and potentials for future improvement

  2020cites this paper
• N-Cadherin mRNA Levels in Peripheral Blood Could Be a Potential Indicator of New Metastases in Breast Cancer: A Pilot Study

  2020cites this paper
• CMAR_A_272685 9375..9387

  2020cites this paper
• Overall survival analysis in patients with metastatic breast cancer and liver or lung metastases treated with eribulin, gemcitabine, or capecitabine

  2020cites this paper
• Current treatment landscape for patients with locally recurrent inoperable or metastatic triple-negative breast cancer: a systematic literature review

  2019cites this paper
• Quality of life outcomes including neuropathy-associated scale from a phase II, multicenter, randomized trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy for HER2-negative metastatic breast cancer: Korean Cancer Study Group Trial (KCSG BR13-11)

  2019cites this paper
• A population pharmacokinetic analysis of the oral CYP17 lyase and androgen receptor inhibitor seviteronel in patients with advanced/metastatic castration-resistant prostate cancer or breast cancer

  2019cites this paper
• Real‐life activity of eribulin mesylate among metastatic breast cancer patients in the multicenter national observational ESME program

  2019cites this paper
• Impact of the number of prior chemotherapy regimens on outcomes for patients with metastatic breast cancer treated with eribulin: A post hoc pooled analysis

  2019cites this paper
• Eribulin in Triple Negative Metastatic Breast Cancer: Critic Interpretation of Current Evidence and Projection for Future Scenarios

  2019cites this paper
• A phase I/II trial of olaparib tablet in combination with eribulin in Japanese patients with advanced or metastatic triple-negative breast cancer previously treated with anthracyclines and taxanes.

  2019cites this paper
• Perspectives on the mechanism of action and clinical application of eribulin for metastatic breast cancer.

  2019cites this paper
• The safety of eribulin for the treatment of metastatic breast cancer

  2019influential citation
• Gene Alterations in Triple-Negative Breast Cancer Patients in a Phase I/II Study of Eribulin and Olaparib Combination Therapy

  2019cites this paper
• Eribulin Promotes Antitumor Immune Responses in Patients with Locally Advanced or Metastatic Breast Cancer.

  2018cites this paper
• Subgroup analysis of patients with HER2-negative metastatic breast cancer in the second-line setting from a phase 3, open-label, randomized study of eribulin mesilate versus capecitabine

  2018cites this paper
• The role of capecitabine and eribulin in the treatment of metastatic HER2-negative metastatic breast cancer

  2018cites this paper
• A multicenter, observational study of metastatic breast cancer patients who were treated with eribulin mesylate or taxane‐based regimens

  2018cites this paper
• Effect of eribulin on patients with metastatic breast cancer: multicenter retrospective observational study in Taiwan

  2018cites this paper
• Significant Association Between Low Baseline Neutrophil‐to‐Lymphocyte Ratio and Improved Progression‐free Survival of Patients With Locally Advanced or Metastatic Breast Cancer Treated With Eribulin But Not With Nab‐Paclitaxel

  2018cites this paper
• Balixafortide plus eribulin in HER2-negative metastatic breast cancer: a phase 1, single-arm, dose-escalation trial.

  2018cites this paper
• Chemotherapy-induced peripheral neuropathy in breast cancer patients treated with eribulin: interim data from a post-marketing observational study

  2018cites this paper
• Efficacy and toxicity of eribulin treatment in metastatic breast cancer patients

  2018cites this paper
• Safety and efficacy of eribulin for "real-world" older patients with metastatic breast cancer.

  2017cites this paper
• New Therapeutic Strategies for Triple-Negative Breast Cancer.

  2017cites this paper
• Classic cytotoxic drugs: a narrow path for regulatory approval.

  2017cites this paper
• Eribulin for metastatic breast cancer (MBC) treatment: a retrospective, multicenter study based in Campania, south Italy (Eri-001 trial)

  2017cites this paper
• Safety Results and Analysis of Eribulin Efficacy according to Previous Microtubules-Inhibitors Sensitivity in the French Prospective Expanded Access Program for Heavily Pre-treated Metastatic Breast Cancer

  2017cites this paper
• Eribulin in advanced breast cancer: safety, efficacy and new perspectives.

  2017cites this paper
• Long-term treatment with eribulin in heavily pretreated women with metastatic breast cancer: a case series.

  2017cites this paper
• Phase II, multicentre, randomised trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy in patients with HER2-negative metastatic breast cancer.

  2017cites this paper
• The results of the first retrospective data analysis of eribulin application in patients with metastatic breast cancer in actual clinical practice in Russia

  2016cites this paper
• Costs associated with Eribulin treatment for patients with metastatic breast cancer in a comprehensive cancer center in France.

  2016cites this paper